See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $297B | 4.6x | 10.0x | |
| $191B | 3.1x | 7.7x | |
| $128B | 2.4x | 8.1x | |
| $122B | 2.8x | 8.3x | |
| $66.2B | 4.1x | 12.2x | |
| $57.5B | 6.7x | 21.6x | |
| $9.6B | 5.0x | -3.0x | |
| $8.4B | 4.1x | -44.1x | |
| $8.4B | 2.7x | -6.8x | |
| $8.0B | 27.0x | 636.9x | |
| $7.9B | 8.1x | 26.3x | |
| $4.4B | n/a | -5.2x | |
| $4.2B | 9.9x | 30.3x | |
| $3.6B | 5.3x | 14.3x | |
| $3.5B | n/a | n/a | |
| $2.6B | 23.2x | n/a | |
| $2.6B | 6.2x | 23.3x | |
| $2.6B | 7.2x | 25.0x | |
| $2.6B | n/a | n/a | |
| $2.3B | n/a | n/a | |
| $2.2B | 4.9x | -78.1x | |
| $2.1B | 264.3x | -9.8x | |
| $2.0B | 2.1x | 5.9x | |
| $1.9B | 7.6x | -5.2x | |
| $1.7B | 6.6x | 282.4x | |
| $1.5B | n/a | n/a | |
| $1.4B | n/a | n/a | |
| $1.4B | 4.1x | 56.6x | |
| $1.3B | 7.0x | 19.0x | |
| $1.2B | n/a | n/a | |
| $1.2B | 475.9x | -4.8x | |
| $1.2B | 463.7x | -8.1x | |
| $1.2B | n/a | n/a | |
| $1.2B | n/a | n/a | |
| $1.0B | 34.1x | -28.3x | |
| $1.0B | 12.6x | -31.8x | |
| $1.0B | 4.9x | -37.1x | |
| $923M | 4.6x | -18.0x | |
| $901M | 5.7x | 12.1x | |
| $860M | n/a | n/a | |
| $745M | 15.9x | -3.8x | |
| $742M | 3.9x | n/a | |
| $742M | n/a | -9.6x | |
| $670M | 0.6x | 1.8x | |
| $629M | 14.6x | -4.2x | |
| $628M | 12.5x | -11.3x | |
| $599M | 7.2x | -55.2x | |
| $578M | n/a | n/a | |
| $539M | n/a | n/a | |
| $489M | n/a | n/a | |
| $485M | n/a | n/a | |
| $477M | n/a | n/a | |
| $469M | 83.7x | n/a | |
| $442M | n/a | n/a | |
| $424M | n/a | n/a | |
| $411M | 2.3x | 9.3x | |
| $408M | 19.6x | -0.8x | |
| $383M | 304.1x | -1.2x | |
| $346M | n/a | n/a | |
| $337M | n/a | n/a | |
| $330M | n/a | -1.9x | |
| $314M | n/a | n/a | |
| $311M | n/a | -11.3x | |
| $292M | n/a | n/a | |
| $246M | 10942.2x | -1.4x | |
| $242M | n/a | -9.4x | |
| $234M | n/a | -5.1x | |
| $217M | 180.9x | -4.5x | |
| $213M | 6.4x | n/a | |
| $209M | 115075.7x | -1.0x | |
| $197M | n/a | n/a | |
| $180M | 2.4x | -0.7x | |
| $175M | 1.3x | n/a | |
| $164M | 15.2x | -4.2x | |
| $156M | 55.1x | -8.2x | |
| $134M | n/a | n/a | |
| $133M | n/a | n/a | |
| $128M | n/a | n/a | |
| $127M | n/a | n/a | |
| $127M | 2.6x | -43.5x | |
| $124M | n/a | n/a | |
| $107M | n/a | n/a | |
| $104M | n/a | n/a | |
| $102M | 0.8x | 2.7x | |
| $95.8M | n/a | -3.8x | |
| $95.4M | n/a | n/a | |
| $92.6M | n/a | n/a | |
| $82.4M | 41.9x | n/a | |
| $75.0M | 10.4x | n/a | |
| $73.4M | 12.4x | n/a | |
| $70.5M | n/a | n/a | |
| $68.0M | n/a | -0.4x | |
| $67.1M | 21.2x | -1.9x | |
| $66.4M | 751.6x | n/a | |
| $55.9M | n/a | n/a | |
| $53.6M | n/a | n/a | |
| $53.3M | 1.2x | -0.3x | |
| $50.3M | n/a | -1.5x | |
| $49.7M | n/a | n/a | |
| $45.3M | n/a | n/a | |
| $43.7M | n/a | n/a | |
| $41.4M | n/a | n/a | |
| $40.7M | n/a | n/a | |
| $37.1M | n/a | n/a | |
| $27.9M | n/a | -0.4x | |
| $27.9M | 19.9x | -1.7x | |
| $22.7M | n/a | n/a | |
| $22.2M | n/a | n/a | |
| $20.4M | 2.8x | n/a | |
| $20.4M | n/a | n/a | |
| $18.0M | n/a | n/a | |
| $16.1M | 3.2x | n/a | |
| $15.8M | 5.1x | -1.1x | |
| $13.0M | 194.4x | n/a | |
| $12.9M | 12.9x | -0.5x | |
| $9.0M | 333.6x | n/a | |
| $8.3M | 0.8x | n/a | |
| $7.9M | n/a | n/a | |
| $6.4M | 0.1x | n/a | |
| $5.8M | 2.3x | n/a | |
| $2.9M | 0.5x | n/a | |
| $0.9M | n/a | -0.0x | |
| -$10.5M | -3.7x | n/a | |
| -$15.1M | -2.3x | 0.1x | |
| -$20.2M | -1.9x | 0.2x | |
| -$31.7M | n/a | n/a | |
| -$50.6M | n/a | n/a | |
| -$57.2M | n/a | n/a | |
| -$84.4M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies